立体定向分割放疗方案加用仑伐替尼治疗原发性肝癌的效果研究  

Study on the Effect of Stereotactic Radiotherapy Combined with Lenvatinib in the Treatment of Primary Liver Cancer

作　　者：曹自昌 贾彦民[2] 张静[3] 董九炎 CAO Zichang;JIA Yanmin;ZHANG Jing;DONG Jiuyan(Department of Oncology,Dongxin Hospital,Zhoukou 466001,Henan,China;Department of Radiotherapy,Zhoukou Central Hospital,Zhoukou 466001,Henan,China;Department of Tumor,Zhoukou Central Hospital,Zhoukou 466001,Henan,China;Department of Infection,Zhoukou Central Hospital,Zhoukou 466001,Henan,China)

机构地区：[1]周口东新医院肿瘤科,河南周口466001 [2]周口市中心医院放疗科,河南周口466001 [3]周口市中心医院肿瘤科,河南周口466001 [4]周口市中心医院感染科,河南周口466001

出　　处：《中国药物滥用防治杂志》2023年第3期486-490,共5页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探讨立体定向分割放疗方案加用仑伐替尼治疗原发性肝癌的效果。方法:选取周口东新医院2018年1月—12月收治的原发性肝癌患者198例,采用随机数字表法将患者分为放疗组(99例)和联合组(99例)。放疗组采用立体定向分割放疗治疗,联合组采用仑伐替尼辅助立体定向分割放疗治疗。比较两组临床疗效、肝功能指标[谷丙转氨酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)]水平、血清聚腺苷酸二磷酸核糖聚合酶-1(PARP-1)、半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)、血管内皮生长因子(VEGF)、甲胎蛋白(AFP)水平、生存率、QLQ-30评分。结果:联合组客观缓解率(52.53%)高于放疗组(37.37%)(P<0.05);联合组治疗3个月后血清ALT、ALB、TBIL水平改善幅度大于放疗组(P<0.05);联合组血清PARP-1、VEGF、AFP水平低于放疗组,血清Caspase-3水平高于放疗组(P<0.05);联合组1年、2年生存率高于放疗组(P<0.05);联合组治疗3个月后QLQ-30评分高于放疗组(P<0.05)。结论:仑伐替尼辅助立体定向分割放疗治疗原发性肝癌患者疗效显著,可改善患者肝功能,促进病情恢复,提高生存率及生活质量。Objective:To investigate the efficacy of lenvatinib assisted stereotactic radiotherapy in the treatment of patients with primary liver cancer.Methods:A total of 198 patients with primary liver cancer admitted to Zhoukou Dongxin Hospital from January 2018 to December 2018 were selected and divided into radiotherapy group(99 cases)and combined group(99 cases)by random number table method.The radiotherapy group was treated with stereotactic radiotherapy,and the combined group was treated with lenvatinib assisted stereotactic radiotherapy.The clinical efficacy,liver function indexes[alanine aminotransferase(ALT),albumin(ALB),total bilirubin(TBIL)]levels,serum of poly(ADP-ribose)polymerase-1(PARP-1),cysteine aspartic protease-3(Caspase-3),vascular endothelial growth factor(VEGF),alpha-fetoprotein(AFP),survival rate and QLQ-30 score were compared between the two groups.Results:The objective remission rate of the combined group(52.53%)was higher than that of the radiotherapy group(37.37%)(P<0.05).The improvement of serum ALT,ALB and TBIL levels in the combined group was greater than that in the radiotherapy group after 3 months of treatment(P<0.05).The levels of serum PARP-1,VEGF and AFP in the combined group were lower than those in the radiotherapy group,and the level of serum Caspase-3 was higher than that in the radiotherapy group(P<0.05).The 1-year and 2-year survival rates of the combined group were higher than those of the radiotherapy group(P<0.05).The QLQ-30 score of the combined group was higher than that of the radiotherapy group after 3 months of treatment(P<0.05).Conclusion:Lenvatinib assisted stereotactic radiotherapy is effective in the treatment of patients with primary liver cancer,which can improve liver function,promote disease recovery,and improve survival rate and quality of life.

关 键 词：仑伐替尼 立体定向分割放疗 原发性肝癌 PARP-1 CASPASE-3 

分 类 号：R735.7[医药卫生—肿瘤]